AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:18:08 2024-04-19 am EDT			5-day change	1st Jan Change
165.4 ^USD	+0.47%		+1.78%	+6.58%

02:44pm	Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	MT
02:27pm	Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	MT

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on November 15, 2022

September 09, 2022 at 10:27 am EDT

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable November 15, 2022, to stockholders of record at the close of business on October 14, 2022.

Latest news about AbbVie Inc.

Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	08:44am	MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	08:27am	MT
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
AbbVie Says Potential Treatment for Giant Cell Arteritis Met Endpoints in Phase 3 Study	Apr. 18	MT
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint	Apr. 18	DJ
AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients with Giant Cell Arteritis	Apr. 18	CI
OSE: licensing agreement with AbbVie enters into force	Apr. 17	CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	Apr. 17	MT
Medincell: share price rises following agreement with AbbVie	Apr. 17	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	Apr. 16	DJ
AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug	Apr. 12	MT
AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine	Apr. 12	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
AbbVie Flags Hit to Q1 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	Apr. 04	MT
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	Mar. 27	MT
Deals of the day-Mergers and acquisitions	Mar. 25	RE
Sector Update: Health Care Stocks Decline Late Afternoon	Mar. 25	MT
Top Midday Gainers	Mar. 25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 25	MT
Top Midday News: Boeing CEO to Step Down; United Airlines to Face Tight FAA Scrutiny; Barclays Upgrades Disney to Overweight; EU Opens Probe Into Apple, Meta, and Google; China to Block Use of Intel, AMD Chips; Ericsson Announces 1,200 Job Cuts in Sweden	Mar. 25	MT
Global markets live: United Airlines, Qualcomm, Amazon, Nissan, Boeing...	Mar. 25

Chart AbbVie Inc.

Duration

Period

More charts

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

164.7 USD

Average target price

184 USD

Spread / Average Target

+11.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+6.58%	292B
ELI LILLY AND COMPANY	+27.67%	672B
NOVO NORDISK A/S	+24.68%	550B
JOHNSON & JOHNSON	-6.76%	351B
MERCK & CO., INC.	+15.01%	317B
ASTRAZENECA PLC	+2.83%	211B
NOVARTIS AG	0.00%	203B
PFIZER, INC.	-11.58%	144B
AMGEN INC.	-8.43%	141B
SANOFI	-3.69%	113B

Other Pharmaceuticals

AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on November 15, 2022

EPS Revisions